Phase II Trial of Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer, With Assessment of Methylguanine-Dna Methyltransferase as a Potential Biomarker
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-11-2059
Full Text
Open PDFAbstract
Available in full text
Date
January 6, 2012
Authors
Publisher
American Association for Cancer Research (AACR)